Page 213 - Read Online

Giakoustidis et al. Hepatoma Res 2017;3:205-8 Hepatoma Research
DOI: 10.20517/2394-5079.2017.29
www.hrjournal.net
Case Report Open Access

Total regression of hepatocellular carcinoma

bone metastases, after liver transplantation,

with sorafenib-everolimus

Dimitrios Giakoustidis , Athanasios Apostolos Gargavanis , Nikolaos Salveridis , Evangelos Cholongitas ,
1
2
1
1
Emmanouil Sinakos , Konstantinos Papapolychroniadis , Vassilios Papanikolaou 1
2
1
1 Division of Transplant Surgery, Department of Surgery, Medical School, Aristotle University of Thessaloniki, Hippokration General Hospital, 54642
Thessaloniki, Greece.
2 The 4th Department of Internal Medicine, Medical School, Aristotle University of Thessaloniki, Hippokration General Hospital, 54642 Thessaloniki, Greece.
Correspondence to: Dr. Dimitrios Giakoustidis, Department of Surgery, Medical School, Aristotle University of Thessaloniki, 54642 Thessaloniki,
Greece. E-mail: dgiak@auth.gr
How to cite this article: Giakoustidis D, Gargavanis AA, Salveridis N, Cholongitas E, Sinakos E, Papapolychroniadis K, Papanikolaou V. Total
regression of hepatocellular carcinoma bone metastases, after liver transplantation, with sorafenib-everolimus. Hepatoma Res 2017;3:205-8.

ABSTRACT
Article history: Hepatocellular carcinoma (HCC) represents the 5th commonest malignancy worldwide. Liver
Received: 26 Jun 2017 transplantation consist a radical and most efficient treatment for HCC. Tumor recurrence
Accepted: 29 Aug 2017 or metastases after liver transplantation is not uncommon. Hereby is presented a case of a
Published: 20 Sep 2017 patient transplanted for alcoholic liver disease and HCC and presented with bone metastases
a few months later. Treatment with sorafenib and everolimus showed full regression of
Key words: the metastases. In conclusion, the point of this report is to advertise a single case of total
Liver transplantation, regression of bone lesions due to HCC recurrence, with the combination of mammalian target
hepatocellular carcinoma, of rapamycin and sorafenib, along with radiation.
bone metastases,
sorafenib,
everolimus

INTRODUCTION recurrent HCC after LT. We hereby present a case
[3]
of a patient transplanted for alcoholic liver disease
Hepatocellular carcinoma (HCC) consists a health- (ALD) and HCC that presented with bone metastases
care problem with rising incidence rates. Liver a few months later. He was treated with sorafenib and
[1]
transplantation (LT) is a radical treatment for HCC. In everolimus, showed full regression of the metastases
order a patient with HCC to receive a liver graft, he must and he is still alive 9 years after LT.
fulfill certain enlisting criteria and no extrahepatic
[2]
disease. Tumor recurrence or metastases after liver CASE REPORT
transplantation for HCC is not uncommon. Sorafenib
has been used as rescue therapy in patients with A 63-year-old male patient was enlisted for LT for

Quick Response Code:
This is an open access article distributed under the terms of the Creative Commons Attribution-
NonCommercial-ShareAlike 3.0 License, which allows others to remix, tweak, and build upon the work
non-commercially, as long as the author is credited and the new creations are licensed under the identical terms.

For reprints contact: service@oaepublish.com

© 2017 OAE Publishing Inc. www.oaepublish.com 205